Interventional device developer Boston Scientific of Natick, MA, reported that enrollment has exceeded 13,000 patients in the Taxus Olympia registry, designed to evaluate the safety and performance of its second-generation drug-eluting coronary stent, the Taxus Liberté.
The Natick, MA-based firm said that Taxus Olympia registry plans to enroll up to 27,000 patients for coronary lesion treatment with the Taxus Liberté device, at more than 500 centers worldwide.
By AuntMinnie.com staff writers
August 31, 2006
Related Reading
Boston Scientific posts powerful Q2 sales, July 27, 2006
Boston Scientific debuts IVUS unit, July 14, 2006
Boston Scientific wins J&J patent appeal, June 16, 2006
Boston Scientific gets EC nod for added Liberte uses May 16, 2006
Boston Scientific, J&J get mixed ruling on stent disputes, May 12, 2006
Copyright © 2006 AuntMinnie.com
